KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

West Pharmaceutical Services (WST) Net Margin (2016 - 2026)

West Pharmaceutical Services has reported Net Margin over the past 18 years, most recently at 16.03% for Q1 2026.

  • Quarterly Net Margin rose 365.0% to 16.03% in Q1 2026 from the year-ago period, while the trailing twelve-month figure was 16.4% through Mar 2026, up 74.0% year-over-year, with the annual reading at 15.59% for FY2025, 93.0% down from the prior year.
  • Net Margin was 16.03% for Q1 2026 at West Pharmaceutical Services, up from 15.93% in the prior quarter.
  • Over five years, Net Margin peaked at 23.73% in Q2 2022 and troughed at 12.38% in Q1 2025.
  • The 5-year median for Net Margin is 17.11% (2024), against an average of 17.63%.
  • Biggest five-year swings in Net Margin: crashed -708bps in 2022 and later soared 423bps in 2023.
  • Tracing WST's Net Margin over 5 years: stood at 14.08% in 2022, then grew by 30bps to 18.27% in 2023, then dropped by -6bps to 17.11% in 2024, then decreased by -7bps to 15.93% in 2025, then rose by 1bps to 16.03% in 2026.
  • According to Business Quant data, Net Margin over the past three periods came in at 16.03%, 15.93%, and 17.14% for Q1 2026, Q4 2025, and Q3 2025 respectively.